Pharma Industry Encouraged to Adopt Mobile ePRO for Clinical Trials Efficiency
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, is championing the industry to adopt mobile electronic Patient Reported Outcomes (ePRO) and other electronic Clinical Outcomes Assessments (eCOA) measures to ensure greater clinical trial success. Currently, over 80% of clinical trials experience delays and mobile ePRO can help mitigate these risks by increasing trial efficiency and patient adherence.
Responding to this issue, Exco InTouch will deliver insights into the application of mobile solutions across the clinical research industry, at this year’s 50th annual DIA meeting, taking place 15–19 June in San Diego.
Showcasing their position as the leader in the application of mobile in ePRO, the company will host on-site demonstrations and a series of 5 presentations, featuring industry-leading content from Tim Davis, CEO, Exco InTouch and Judith Teall, Director of Clinical Excellence. For those looking to learn more about the high value that mobile technology can offer to clinical trials, presentations will include ‘Electronic Clinical Outcome Assessments: Coming to a Device Near You!’ and ‘The Use of Mobile Technology to Place Patients at the Center of Clinical Trials’.
Exco InTouch, which will be exhibiting at booth 2116, will also demonstrate its approach to BYOD (bring your own device) and, more broadly to data capture and patient engagement services across clinical research programs. By enhancing clinical outcomes through improved patient compliance and data capture, their solutions will enhance trial efficiencies, ultimately speeding up potential times to market.
Tim Davis, CEO and co-founder of Exco InTouch commented: “Our presence at the DIA annual meeting will enable us to showcase our strengths as the industry leaders of mobile technology applications within clinical trials and the ease in which our services successfully captures ePRO. We are very much aware of the importance of making the clinical trial process simple for patients, and our technology, which enables a BYOD approach where appropriate, helps further increase patient engagement.”
He continued: “The global pharma industry is increasingly looking at ways to ensure its trials are run on time and with greater adherence. I would encourage everyone who wants to learn more about the benefits of our approach and the instruments and technologies that we have to offer, to visit our booth at DIA (2116) where we would be delighted to demonstrate our services first hand."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.